• Je něco špatně v tomto záznamu ?

How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration

O. Májek, M. Babjuk, MJ. Roobol, O. Bratt, H. Van Poppel, R. Zachoval, J. Ferda, M. Koudelková, O. Ngo, J. Gregor, S. Collen, K. Hejduk, L. Dušek, V. Válek

. 2023 ; 53 (-) : 106-108. [pub] 20230608

Status neindexováno Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015813

UNLABELLED: An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. PATIENT SUMMARY: Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015813
003      
CZ-PrNML
005      
20231020093634.0
007      
ta
008      
231010s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euros.2023.05.011 $2 doi
035    __
$a (PubMed)37441346
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Májek, Ondřej $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
245    10
$a How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration / $c O. Májek, M. Babjuk, MJ. Roobol, O. Bratt, H. Van Poppel, R. Zachoval, J. Ferda, M. Koudelková, O. Ngo, J. Gregor, S. Collen, K. Hejduk, L. Dušek, V. Válek
520    9_
$a UNLABELLED: An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. PATIENT SUMMARY: Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Babjuk, Marek $u Department of Urology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czechia
700    1_
$a Roobol, Monique J $u Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands
700    1_
$a Bratt, Ola $u Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden $u Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
700    1_
$a Van Poppel, Hendrik $u European Association of Urology Policy Office, Arnhem, The Netherlands $u Department of Urology, KU Leuven, Leuven, Belgium
700    1_
$a Zachoval, Roman $u Department of Urology, 3rd Faculty of Medicine of Charles University and Faculty Thomayer Hospital, Prague, Czechia
700    1_
$a Ferda, Jiří $u Department of Imaging Methods, Medical Faculty Pilsen, Charles University, University Hospital Pilsen, Pilsen, Czechia
700    1_
$a Koudelková, Marcela $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Ngo, Ondřej $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Gregor, Jakub $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Collen, Sarah $u European Association of Urology Policy Office, Arnhem, The Netherlands
700    1_
$a Hejduk, Karel $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Dušek, Ladislav $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Válek, Vlastimil $u Faculty of Medicine, Masaryk University, Brno, Czechia $u Ministry of Health of the Czech Republic, Prague, Czechia
773    0_
$w MED00207999 $t European urology open science $x 2666-1683 $g Roč. 53, č. - (2023), s. 106-108
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37441346 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093628 $b ABA008
999    __
$a ok $b bmc $g 1997279 $s 1202175
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 53 $c - $d 106-108 $e 20230608 $i 2666-1683 $m European urology open science $n Eur Urol Open Sci $x MED00207999
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace